Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics (NASDAQ: INDP) presented new cohort data from its Phase 1 clinical trial of Decoy20 at the ASCO Annual Meeting, confirming the original 'Pulse-Prime' hypothesis.
May 29, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics presented new data from its Phase 1 clinical trial of Decoy20, confirming the 'Pulse-Prime' hypothesis. This could positively impact the stock price as it demonstrates progress in their innovative cancer treatment.
The confirmation of the 'Pulse-Prime' hypothesis through new data from the Phase 1 trial of Decoy20 is a significant milestone for Indaptus Therapeutics. This progress in their clinical trials is likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100